These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35878782)

  • 1. No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
    Saleem A; Waqar E; Shuja SH; Naeem U; Moeed A; Rais H; Ahmed J
    Transfus Clin Biol; 2023 Feb; 30(1):69-74. PubMed ID: 35878782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
    Ricchi P; Meloni A; Pistoia L; Gamberini MR; Cuccia L; Allò M; Putti MC; Spasiano A; Rosso R; Cecinati V; Righi R; Renne S; Peritore G; Vallone A; Positano V; Quaia E; Cademartiri F; Pepe A
    Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.
    Tripathy I; Panja A; Dolai TK; Mallick AK
    Hemoglobin; 2021 Sep; 45(5):296-302. PubMed ID: 34758688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
    Xia S; Zhang W; Huang L; Jiang H
    PLoS One; 2013; 8(12):e82662. PubMed ID: 24376563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
    Musallam KM; Barella S; Origa R; Ferrero GB; Lisi R; Pasanisi A; Longo F; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes.
    Yusuf S; Herdata HN; Edward ED; Khairunnisa K
    F1000Res; 2023; 12():154. PubMed ID: 39233713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY; Li Q; Chen JJ; Chen GF; Li CG
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
    Premawardhena A; Perera C; Wijethilaka MN; Wanasinghe SK; Rajakaruna RHMG; Samarasinghe RANKK; Williams S; Mettananda S
    BMJ Open; 2024 Feb; 14(2):e077342. PubMed ID: 38331857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on hearing after long-term use of iron chelators in beta-thalassemia: Over twenty years of longitudinal follow-up.
    Aldè M; Ambrosetti U; Giuditta M; Cassinerio E; Piatti G
    Auris Nasus Larynx; 2024 Apr; 51(2):271-275. PubMed ID: 37903661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
    Sridharan K; Sivaramakrishnan G
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
    Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
    DivakarJose RR; Delhikumar CG; Ram Kumar G
    Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
    Bentley A; Gillard S; Spino M; Connelly J; Tricta F
    Pharmacoeconomics; 2013 Sep; 31(9):807-22. PubMed ID: 23868464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
    Merchant R; Ahmed J; Krishnan P; Jankharia B
    Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.